## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Kesponse	s)															
1. Name and Address of Reporting Person * GOLDBERG MORTON				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director 10% Owner Officer (give title below) Other (specify below)					
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 11/12/2019							y/Year)						
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)							h/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, i any (Month/Day/Year		ĺ	Code (Instr. 8)		4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5)		of (D)	Beneficia	t of Securities lly Owned Following Transaction(s)		Ownership Form:	7. Nature of Indirect Beneficial Ownership	
						i cai)		ode	V	Amour	(A) or (D)	Price	(msu. 3 a	iisii. 3 aid 4)		or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock		11/12/2019				S		2,001	D	\$ 4.29	1,961 (1	1,961 <sup>(1)</sup>		D			
Reminder:	Report on a s	separate line fo	r each class of secur	Derivat	tive Sec	curiti	es Ac	quire	Pers cont the f	ons whained if	no respo n this fo splays a	rm ar curre	e not requently valid	ction of inf uired to res OMB conf	spond unle	ess	1474 (9-02)
	_	1						ts, op			tible secu			I			
Security	2. Conversion or Exercise Price of Derivative Security		Execution Day	4. Transaction Code Year) (Instr. 8)		tion (	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercis and Expiration (Month/Day/Yo		on Date	Am Uno Sec	derlying urities ttr. 3 and Security (Instr. 5)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Owners Form of Derivat Securit Direct of Or India	Beneficia ive Ownersh y: (Instr. 4) D)
					Code	V	(A)	(D)	Date Exer	cisable	Expiration Date	on Titl	Amount or Number of Shares				

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
GOLDBERG MORTON C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452	X					

### **Signatures**

/s/ Sarah Romano, Attorney-in-Fact*	11/13/2019		
**Signature of Reporting Person	Date		

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Effective as of 08/30/2019, the Issuer effected a 1-for-15 reverse split of its common stock. The number of shares reflects the reverse stock split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.